Method for Producing Retinal Tissue and Retina-Related Cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/JP2014/072065, filed Aug 22, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,501,724 | Method for Producing Retinal Tissue and Retina-Related Cells In force · High confidence | Sumitomo Chemical Company, Limited and RIKEN | In force | High confidence | ||
| US 11,473,056 | Method for Producing Retinal Tissue and Retina-Related Cells In force · Medium confidence | Sumitomo Chemical Company, Limited and RIKEN | In force | Medium confidence | ||
| US 12,378,520 | Method for Producing Retinal Tissue and Retina-Related Cells In force · Medium confidence | Sumitomo Chemical Company, Limited and RIKEN | In force | Medium confidence | ||
| Application 19/284,393 | Method for Producing Retinal Tissue and Retina-Related Cells Pending Not granted | Sumitomo Chemical Company, Limited and RIKEN | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by RIKEN.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.